In this context it will also be important to address whether ADORA agonists can overcome current limitations of SMO inhibitors for the treatment of acquired or de novo SMO inhibitor resistant malignancies including cancers with SMO-independent GLI activation [9, 46, 48, 50, 63-65]. This evidence concerns the gene SMO and cancer.